India's Hetero Labs Ltd has received regulatory approval to sell its version of anti-viral drug favipiravir to treat Covid-19, Reuters reported while quoting a statement by the drug making company.

The drug, priced at 59 Indian rupees (79 cents) per tablet, is approved to treat mild to moderate Covid-19 and will be available at drug stores from Wednesday, privately held Hetero said in a statement.

Favipiravir and another anti-viral treatment, remdesivir, have emerged as the most sought after medicines to treat Covid-19 in India, which had already approved the drugs as emergency treatments to fight the outbreak.